CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
Alexandre, J × Brown, C Coeffic, D Raban, N Pfisterer, J Mäenpää, J Chalchal, H Fitzharris, B Volgger, B Vergote, Ignace Pisano, C Ferrero, A Pujade-Lauraine, E #
British Journal of Cancer vol:106 issue:4 pages:633-7
CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.